As the first HER2-targeted antibody–drug conjugate (ADC) to be approved for clinical use, T-DM1 has shown some benefit in the treatment of HER2+ breast cancer patients that are refractory to trastuzumab alone7,10. This evidence concerns the gene ERBB2 and breast carcinoma.